joined by an azo bond, and its antibactericidal effect, [3, 6, 19] but not related to the treatment with mesalazine. [19] In spite of there are some studies on the protective effect of 5-ASA and the antibiotic therapy, [9, 20] this still remains controversial, [8, 21, 22] inviting to speculate again about the infectious etiopathogeny of CD. Only some Italian authors, [20, 27] using the 13 C-UBT for H. pylori detection, their results showed no statistically significant differences between the prevalence of H. pylori infection in patients with IBD and controls.
In our service, as a routine procedure, 13 C-UBT (Otsuka method) has been required to all patients with gastrointestinal (GI) disorders to detect the presence of H. pylori and avoiding leaving affected patients without treatment (previously, none of them received any doses of sulfasalazine). In our clinical experience, we have found that many patients with IBD have positive 13 C-UBT tests for the presence of H. pylori-pos, similar to healthy patients.
This fact led us to perform a prospective and longitudinal study to analyze our results with the aim of determining, through the results of the 13 C-UBT, the frequency of H. pylori active infection in patients with GI disorders compared with a control group. Furthermore, determine if the H. pylori eradication in H. pylori-pos patients showed some relation with the number of recurrences and some effect over the natural history of the disease.
Methods
For the selection of the patients, a retrospective, multicenter observational analysis was carried out of a database of a center with local CEIC. The purpose of the study was to analyze the breath test 
Control Group
A total of 20 asymptomatic patients without gastric pathology recruited in the outpatient gastroenterology service, 12 women and 8 men (aged 20-83 years, average 50.6).
Case Group
A total of 105 patients were selected with GI disorders: Celiac disease: n=10, seven women and three men (aged 10-79 years, average 39); microscopic colitis: n=15, 10 women and 5 men (aged 20-72 years, average 50); ulcerative colitis: n=40, 23 women and 17 men (aged 26-74 years, average 37.3); and CD: n=40, 20 women and 20 men (aged 17-60 years, average 36.6).
Inclusion Criteria
Patients with consistent anatomopathological diagnosis of GI disorders (endoscopy, biopsy and laboratory tests), patients with celiac disease that did not take any gluten-free diet before 13 C-UBT, and patients with microscopic colitis, ulcerative colitis, and CD, in remission, receiving maintenance therapy with probiotics, 5-ASA or azathioprine, after taking them in a staggered dose were included in this study.
Exclusion Criteria
Patients in treatment with sulfasalazine as chronic maintenance therapy or having previously received antibiotic treatment, and patients with indeterminate colitis (10% of our entire series), were discarded. This condition was included for avoiding the potential protective effect against H. pylori infection, mentioned in the literature reviewed.
A granulocyte apheresis was carried out in some patients with UC 4/40 (10%) and CD 4/40 (10%).
The 40% (42/105) of cases undergone gastroscopy and biopsy and the data were consistent with the positivity or negativity of 13 C-UBT that was considered negative when the result was less or equal to 2.5% (therefore, absence of H. pylori-neg) and positive when this was >2.5%. The specialist who performed the 13 C-UBT was blind for the diagnosis of patients included in this study.
Patients with H. pylori-pos were treated for 10 days with one of these triple therapies:
• OCA: Omeprazole 20 mg, clarithromycin 500 mg, and amoxicillin 1 g every 12 h.
• OFA: Omeprazole-20 mg, 500 mg metronidazole, and amoxicillin 1 g every 12 h.
None of the 80 patients with IBD: Ulcerative colitis (40 cases) and CD (40 cases) received previously any doses of sulfasalazine.
All were followed up for 48 months. The number of recurrences was assessed.
Statistical Analysis
Proof of the Student's t-test for quantitative variables or Fisher's exact test for qualitative variables was used. Odds ratio (OR) for comparing the results obtained with the 13 C-UBT in subgroups of patients with IBD and celiac disease or microscopic colitis compared to those observed in the control group and adjusting for age and sex distributions were estimated by logistic regression (STATA 10.1).
Results

13
C-UBT
In the control group (n=20), the positivity of H. pylori was 40% (8/20) . In the case group (n=105), the average of positivity was 42% (47/105). In detail: Patients with microscopic colitis 46% (7/15) and celiac disease 30% (3/10), in the ulcerative colitis group 40% (16/40), and CD group 52% (21/40).
In overall, in the IBD group, the positivity was 46% (37/80).
Comparing the results with the control group, after controlling for age and sex: Patients with IBD showed a similar positivity to 13 C-UBT (OR=0.99; 95% CI: 0.32-3.05). Patients with celiac disease or microscopic colitis, compared to controls, gave similar results (OR=0.93; 95% CI: 0.25-3.44).
Treatments
In the IDB group, 76% (28/37) of patients with H. pylori -pos (14 with UC and 14 with EC) had an effective eradication with one of the triple therapies (OCA or OFA) for 10 days and a follow-up of 48 months. Only in 9 patients (24%), H. pylori was not eradicated. The clinical follow-up of recurrences was carried out every 3 months, for an average of 48 months (4 years) (range 2-7 years). The 28 patients with effective H. pylori eradication, were compared with the 10 patients of the IBD group with a negative result of Along the follow-up period, 48 months (median: 36 months), of patients in clinical remission (effective treatment eradication), 78.6% with UC (11/14) and 93% with CD (13/14), and 86% with IBD (24/28) (95% CI 73-99%), did not show any clinical recurrences of the disease, while patients with no treatment effective eradication, showed recurrences. Only 40% of patients with H. pylori -(4/10) (95% CI 9.6-70%), p<0.05, no outbreak was observed (Fig. 1) .
Discussion
Although, currently, it turns to speculate on infectious etiology of CD, [7] reviewed in this study, many studies have attributed the low prevalence of H. pylori in patients with IBD to the effect of chronic maintenance therapy with sulfasalazine (bactericidal) instead of mesalazine. Moreover, some authors also believe in the protective effect of 5-ASA, [20] unlikely, because it is released beyond the stomach.
The eradication of H. pylori in patients with IBD appears to have a beneficial effect on the natural history of the disease, although studies with more cases would be needed.
Numerous studies have studied the frequency and prevalence of H. pylori infection in patients with IBD using different diagnostic methodologies.
Serology in Peripheral Blood (IgG and IgA Antibodies)
A lower prevalence of H. pylori-pos in IBD compared to the control group, with statistically significant results in most comparative studies is shown. [8] The largest prospective comparative study, 100 cases included per group, [3] shows statistically significant differences not attributable to treatment with sulfasalazine (H. pylori diagnostic by IgA antibody). In another study, in which the diagnosis was performed by IgG determining, [4] results were not statistically significant. GI biopsies with or without H. pylori determination: [1, [9] [10] [11] [12] [13] [14] [15] [16] [17] 29] The largest prospective comparative study [12] demonstrated a 63% of endoscopic lesions on CD and chronic gastroduodenitis not associated with H. pylori-pos. Another controlled study, [13] but with differences in age, shows statistically significant differences attributable to antibiotic treatment and endoscopic lesions in 92.2% of CD patients. 13 C-UBT in the expired breath: [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] The largest prospective and controlled study did not demonstrate statistically significant differences, [19] while Asian studies did (Table 1) . [21, 24, 27, 30, 31] 
Combination of Several Methods
Serology and biopsies, [3] serology and 13 C-UBT, [18] biopsies and 13 C-UBT. [21, 22] A large, controlled study showed a statistically significant difference. [21] When most sensitive and specific methods are utilized, less convincing results are obtained. Few written reports have reported the substantial difference. Our results suggest that the frequency is similar when compared to asymptomatic subjects and even, tends to be higher in patients with CD than with UC and controls. In comparison with asymptomatic patients, after controlling for the different age and sex, regarding the distribution among groups, we did not No recurrences 86% 40% find any difference. In fact, in our study patients with IDB and H. pylori eradicated, showed clinical improvement and reduced the number of recurrences over 4 years follow-up. Hence, it seems that H. pylori could play a role in the pathogenesis of IBD and the natural history of the disease.
However, our results are limited by the number of patients studied (similar sample size to previously published works (Table 1) ) as is reflected in the confidence intervals (contain the null value but is broad).
Some studies have identified other species of H. pylori in the digestive tract of patients with IBD, CD, or UC. [32] [33] [34] [35] [36] [37] Recently, it has been speculated again on the infectious etiology of IBD, [38, 39] attributing potential pathogenesis to some Helicobacter species or Mycobacterium avium paratuberculosis. [40] [41] [42] Some sources do not assign any role to the effect of antibiotic treatment. The implication of the H. pylori presence still remains controversial. [7, 20] Other researchers attribute the low prevalence of H. pylori infection in patients with IBD, to previous antibiotic treatment. [14, 35, 43, 44] Triantafillidis et al. match with these results, because patients who had not taken antibiotics had a prevalence of 55% versus 55.1% of controls. [43] [30] 229 IBD 248 controls 27.1% 47.9% (S) Jin et al. [31] 153 UC 30.5% 121 controls 57% (S) CD: Crohn's disease, IBD: Inflammatory bowel disease, UC: Ulcerative colitis, COPD: Chronic obstructive pulmonary disease, P: Prospective, C: Controlled and matched by age and gender, NS: Not significant, S: Significant.
Taking into account that H. pylori causes granulomatous gastritis in the antrum; [45] however, patients with CD disease are not often infected by this microorganism. [13] Only one patient with CD of our study (1/40, 2.5%) showed the presence of the disease located at the stomach, and regarding H. pylori, the macroscopic vision, biopsy, and 13 C-UBT were negative. In addition, frequent endoscopic lesions, [10, 13, 14] focal gastritis, [10, 16] focal cryptitis, [17] and CD8 focal gastritis [46] have recently been described in patients with IBD.
Most of our patients with IBD and H. pylori -pos eradicated, remained asymptomatic for an average of 48 months of follow-up. Only 4 patients (14%) had clinical recurrences in monitoring, confirmed by endoscopy.
It is worth noting that an oligosymptomatic patient, with UC and H. pylori -pos, had a major outbreak of diarrhea caused by Clostridium botulinum and after eradication, developed IBD; as recently it has published in other studies. [47, 48, 49] A recent review, [49] has arrived at the same conclusion, pointing that the relationship between H. pylori infection and IBD still remains controversial. In spite of other groups do not support our thesis, [30, 31, 50] the results obtained provide enough data to take them into consideration and might guide new studies to clarify this possible relationship (Table 1) .
